Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy

Basit Öğe Kaydı
dc.contributor.authorYildirim, Eda Caliskan
dc.contributor.authorErgun, Yakup
dc.date.accessioned2025-02-22T14:08:38Z
dc.date.available2025-02-22T14:08:38Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractHepatocellular carcinoma (HCC) remains a major challenge in oncology, being a leading cause of cancer-related mortality worldwide. Early-stage HCC is typically treated with surgical resection, transplantation, or ablation, while advanced-stage HCC relies on systemic therapies like sorafenib and newer combinations such as atezolizumab-bevacizumab. Despite these advancements, there is still a need for effective treatments for unresectable HCC, especially in cases with macroscopic vascular invasion. Hepatic arterial infusion chemotherapy (HAIC) has demonstrated promising outcomes in Asia for the treatment of unresectable HCC, yet its application in Western countries has been relatively limited. This letter reviews the recent meta-analysis by Zhou et al published in the World Journal of Gastrointestinal Oncology, which demonstrates the efficacy and safety of HAIC vs sorafenib. The analysis includes 9 randomized controlled trials and 35 cohort studies, highlighting significant improvements in overall survival, progression-free survival, and objective response rates with HAIC and its combinations. The editorial explores the reasons behind the limited use of HAIC in Western countries. It underscores the potential of HAIC to enhance treatment outcomes for advanced HCC and calls for more research and broader adoption of HAIC in clinical practice globally.en_US
dc.identifier.doi10.4251/wjgo.v16.i12.4757
dc.identifier.issn1948-5204
dc.identifier.issue12en_US
dc.identifier.pmid39678807en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.4251/wjgo.v16.i12.4757
dc.identifier.urihttps://hdl.handle.net/11468/29533
dc.identifier.volume16en_US
dc.identifier.wosWOS:001361096400012
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherBaishideng Publishing Group Incen_US
dc.relation.ispartofWorld Journal of Gastrointestinal Oncologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectHepatocellular carcinomaen_US
dc.subjectHepatic arterial infusion chemotherapyen_US
dc.subjectTyrosine kinase inhibitorsen_US
dc.subjectImmunotherapyen_US
dc.subjectSurvivalen_US
dc.titleAdvancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapyen_US
dc.typeLetteren_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu